Adefovir dipivoxil: Review of a novel acyclic nucleoside analogue

International Journal of Clinical Practice

Volumn 58, Issue 9, 2004, Pages 877-886

  Danta, M ^a   Dusheiko, G ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Adefovir; Adefovir dipivoxil; HBV; Hepatitis B; HIV; Nucleoside analogue; Treatment

Indexed keywords

ACYCLIC NUCLEOSIDE; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; COTRIMOXAZOLE; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIGEN; HYDROXYUREA; IBUPROFEN; INTERFERON; LAMIVUDINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROBENECID;

ABDOMINAL PAIN; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; CLINICAL TRIAL; DIARRHEA; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SENSITIVITY; GASTROINTESTINAL TOXICITY; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY TUBULE DISORDER; LIVER TOXICITY; LIVER TRANSPLANTATION; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY; REVIEW; SEROCONVERSION; SINGLE DRUG DOSE; VIRUS RESISTANCE;

ADENINE; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; PHOSPHONIC ACIDS; TREATMENT OUTCOME;

EID: 7744241924     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2004.00364.x     Document Type: Review

References (75)

1. Kramata P, Votruba I, Otova B, Holy A. Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases alpha, delta and epsilon. Mol Pharmacol 1996; 49: 1005-11.
2. Balzarini J, Naesens L, Herdewijn P et al. Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl) adenine, a selective anti-human immunodeficiency virus agent. Proc Natl Acad Sci USA 1989; 86 (1): 332-6.
3. De Clercq E. New acquisitions in the development of anti-HIV agents. Antiviral Res 1989; 12 (1): 1-19.
4. De Clercq E. Therapeutic potential of phosphonylmethoxyalkylpurines and -pyrimidines as antiviral agents. Drugs Exp Clin Res 1990; 16 (7): 319-26.
5. Lin JC, DeClercq E, Pagano JS. Novel acyclic adenosine analogs inhibit Epstein-Barr virus replication. Antimicrob Agents Chemother 1987; 31 (9): 1431-3.
6. Heijtink RA, De Wilde GA, Kruining J et al. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res 1993; 21: 141-53.
7. Holy A, Votruba I, Merta A et al. Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virus-encoded enzymes in vitro. Antiviral Res 1990; 13 (6): 295-311.
8. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28 (6): 1669-73.
9. Birkus G, Gibbs CS, Cihlar T. Comparative effects of adefovir and selected nucleoside inhibitors of hepatitis B virus DNA polymerase on mitochondrial DNA in liver and skeletal muscle cells. J Viral Hepat 2003; 10 (1): 50-4.
10. Calio R, Villani N, Balestra E et al. Enhancement of natural killer activity and interferon induction by different acyclic nucleoside phosphonates. Antiviral Res 1994; 23 (1): 77-89.
11. Shaw JP, Louie MS, Krishnamurthy VV et al. Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats. Drug Metab Dispos 1997; 25 (3): 362-6.
12. Annaert P, Kinget R, Naesens L, De Clercq E, Augustijns P. Transport, uptake, and metabolism of the bis (pivaloyloxymethyl)-ester prodrug of 9-(2-phosphonylmethoxyethyl) adenine in an in vitro cell culture system of the intestinal mucosa (Caco2). Pharm Res 1997; 14 (4): 492-6.
13. Bronson JJ, Ho HT, De Boeck H et al. Biochemical pharmacology of acyclic nucleotide analogues. Ann N Y Acad Sci 1990; 616: 398-407.
14. Cundy KC, Barditch-Crovo P, Walker RE et al. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrobial Agents Chemotherapy 1995; 39 2401-5.
15. Barditch-Crovo P, Toole J, Hendrix CW et al. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. J Infect Dis 1997; 176 (2): 406-13.
16. Cundy KC, Sue IL, Visor GC et al. Oral formulations of adefovir dipivoxil: in vitro dissolution and in vivo bioavailability in dogs. J Pharm Sci 1997; 86 (12): 1334-8.
17. Ho ES, Lin DC, Mendel DB, Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 2000; 11 (3): 383-93.
18. Mulato AS, Ho ES, Cihlar T. Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther 2000; 295 (1): 10-5.
19. Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, Sweet DH. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol 1999; 56 (3): 570-80.
20. Hosoyamada M, Sekine T, Kanai Y, Endou H. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am J Physiol 1999; 276 (1 Pt 2): F122-8.
21. Tanji N, Tanji K, Kambham N, Markowitz GS, Bell A, D'Agati VD. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol 2001; 32 (7): 734-40.
22. Bendele RA, Richardson FC. Adefovir nephrotoxicity and mitochondrial DNA depletion. Hum Pathol 2002; 33 (5): 574.
23. Biesecker G, Karimi S, Desjardins J et al. Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys and woodchucks. Antiviral Res 2003; 58 (3): 217-25.
24. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348 (9): 800-7.
25. Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348 (9): 808-16.
26. Zoulim F. Assessing hepatitis B virus resistance in vitro and molecular mechanisms of nucleoside resistance. Semin Liver Dis 2002; 22 (Suppl. 1): 23-31.
27. Das K, Xiong X, Yang H et al. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001; 75 (10): 4771-9.
28. Yang H, Westland CE, Delaney WE et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002; 36 (2): 464-73.
29. Nicoll AJ, Angus PW, Chou ST, Luscombe CA, Smallwood RA, Locarnini SA. Demonstration of duck hepatitis B virus in bile duct epithelial cells: Implications for pathogenesis and persistent infection. Hepatology 1997; 25 (2): 463-9.
30. Seigneres B, Martin P, Werle B et al. Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model. Antimicrob Agents Chemother 2003; 47 (6): 1842-52.
31. Westland CE, Yang H, Delaney WE et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003; 38 (1): 96-103.
32. Angus P, Vaughan R, Xiong S et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125 (2): 292-7.
33. Villeneuve JP, Durantel D, Durantel S et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39 (6): 1085-9.
34. Cherrington JM, Mulato AS, Fuller MD, Chen MS. Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro. Antimicrob Agents Chemother 1996; 40 (9): 2212-6.
35. Mulato AS, Lamy PD, Miller MD et al. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy. Antimicrob Agents Chemother 1998; 42 (7): 1620-8.
36. Mulato AS, Cherrington JM. Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses. Antiviral Res 1997; 36 (2): 91-7.
37. Delaugerre C, Marcelin AG, Thibault V et al. Human immunodeficiency virus (HIV) type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine. Antimicrob Agents Chemother 2002; 46 (5): 1586-8.
38. Benhamou Y, Bochet M, Thibault V et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358 (9283): 718-23.
39. Decks SG, Collier A, Lalezari J et al. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J Infect Dis 1997; 176 (6): 1517-23.
40. Kamp W, Schokker J, Cambridge E et al. Effect of weekly adefovir (PMEA) infusions on HIV-1 virus load: results of a phase I/II study. Antivir Ther 1999; 4 (2): 101-7.
41. Kahn J, Lagakos S, Wulfsohn M et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA 1999; 282 (24): 2305-12.
42. Miller MD, Margot NA, Lamy PD et al. Adefovir and tenofovir susceptibilities of HIV-1 after 24-48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408. J Acquir Immune Defic Syndr 2001; 27 (5): 450-8.
43. Fisher EJ, Chaloner K, Cohn DL et al. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS 2001; 15 (13): 1695-700.
44. A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial. HIV Med 2002; 3 (4): 229-38.
45. Gilson RJC, Chopra K, Murray-Lyon I et al. A placebo controlled phase I/II study of adefovir dipivoxil (BIS-POM PMEA) in patients with chronic hepatitis B infection. J Viral Hepat 6: 387-95.
46. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
47. Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334 (22): 1422-7.
48. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34 (4 Pt 1): 617-24.
49. Ling R, Mutimer D, Ahmed N et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24 (3): 711-3.
50. Dienstag JL, Goldin RD, Heathcote EJ et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124 (1): 105-17.
51. Ono-Nita SK, Kato N, Shiratori Y et al. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999; 103 (12): 1635-40.
52. Perrillo R, Schiff E, Yoshida E et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32 (1): 129-34.
53. Walsh KM, Woodall T, Lamy P, Wight DGD, Bloor S, Alexander GJM. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 2001; 49 (3): 436-40.
54. Mutimer D, Feraz-Neto BH, Harrison R et al. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir. Gut 2001; 49 (6 : 860-3.
55. Tillmann HL, Bock CT, Bleck JS et al. Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. Liver Transpl 2003; 9 (2): 191-6.
56. Liaw YF. Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. J Gastroenterol Hepatol 2002; 17 (Suppl. 3): S333-7.
57. Peters MG, Hann HH, Martin P et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126 (1): 91-101.
58. Ockenga J, Tillmann HL, Trautwein C, Stoll M, Manns MP, Schmidt RE. Hepatitis B and C in HIV-infected patients - Prevalence and prognostic value. J Hepatol 1997; 27 (1): 18-24.
59. Sinicco A, Raiteri R, Sciandra M et al. Coinfection and super-infection of hepatitis B virus in patients infected with human immunodeficiency virus: No evidence of faster progression to AIDS. Scand J Infectious Dis 1997; 29 (2): 111-5.
60. Benhamou Y, Bochet M, Thibault V et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30 (5): 1302-6.
61. Thibault V, Benhamou Y, Seguret C et al. Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. J Clin Microbiol 1999; 37 (9): 3013-6.
62. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. NEJM 1993; 329 (25): 1842-7.
63. Grellier L, Mutimer D, Ahmed M et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348 (9036): 1212-5.
64. Mutimer D, Dusheiko G, Barrett C et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: Long-term follow-up. Transplantation 2000; 70 (5): 809-15.
65. Han SH, Kinkhabwala M, Martin P et al. Resolution of recurrent hepatitis B in two liver transplant recipients treated with famciclovir. Am J Gastroenterol 1998; 93 (11): 2245-7.
66. Markowitz JS, Martin P, Conrad AJ et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28 (2): 585-9.
67. Sousa JM, Pareja F, Serrano J et al. Comparison between levels of anti-HBS with a fixed administration dose of HBIG and a combination of HBIG and lamivudine for the prophylaxis of hepatitis B after liver transplantation. Transplant Proc 2003; 35 (2): 723-4.
68. Davies SE, Portmann BC, O'Grady JG et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13: 150-7.
69. Lau JY, Bain VG, Davies SE, O'Grady JG, Alberti A, Alexander GJ. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology 1992; 102: 956-62.
70. Mutimer D, Pillay D, Dragon E et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 1999; 30 (4): 715-21.
71. Mutimer D, Pillay D, Shields P et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000; 46 (1): 107-13.
72. Schiff ER, Lai CL, Hadziyannis S et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38 (6): 1419-27.
73. EASL International Consensus Conference on Hepatitis B, 13-14 September 2002, Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003; 38 (4): 533-40.
74. Le Guerhier F, Thermet A, Guerret S et al. Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model. J Hepatol 2003; 38 (3): 328-34.
75. Dusheiko G. A pill a day, or two, for hepatitis B? Lancet 1999; 353 (9158): 1032-3.